Roche to file MS drug for approval in early 2016; Bristol-Myers' Opdivo scores Early Access spot in U.K.; Boehringer diabetes med falls short in Phase II;

> Roche ($RHHBY) touted success for its MS drug ocrelizumab in two late-stage studies, saying the data puts it on track for regulatory filings in early 2016. Report

> Bristol-Myers Squibb's ($BMY) new cancer immuno-therapy Opdivo scored a spot on the U.K.'s Early Access to Medicines Scheme, the first lung cancer drug to be approved under the program. Report

> Boehringer Ingelheim and its development partner Vitae ($VTAE) saw their diabetes drug VTP-34072 fail to significantly decrease blood sugar in a mid-stage trial. Report

> AstraZeneca's ($AZN) Crestor patent was invalidated by the Brazilian federal courts. Report

> Novartis' ($NVS) eye care unit Alcon won European approval for a new type of lens used in cataract surgery. Release

> Cosmederm Bioscience expanded its itch-relief product line TriClam with two new topical products. Release

And Finally... WPP-owned brand agency The Partners appointed Peter Henshaw from Inventiv Europe as a creative director for its health team. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?